https://www.selleckchem.com/products/arq-197.html
LTHNIPPV also relieved dyspnea and improved exercise capacity and health-related quality of life (HRQL) but showed no significant benefit for improving the forced expiratory volume in one second in predicted (FEV1% pred). Subgroup analysis revealed that the baseline level and reduction in PaCO2 were associated with decreased mortality (baseline PaCO2 ≥ 55 mmHg RR = 0.69, P = 0.02; vs baseline PaCO2 55 mmHg RR = 0.87, P = 0.32; and higher dPaCO2 RR = 0.42, P 0.0001; vs lower dPaCO2 RR = 0.91, P = 0.38). LTHNIPPV significantly r
Like
Comment
Share
